- When considering whether or not a patient is appropriate for FARYDAK regimen, it is important to consider individual response to prior therapy
- For patients who have had a positive experience with BTZ + dexamethasone (dex)—had a good first response (achieved ≥PR), manageable toxicity, and relapsed after a fixed number of BTZ cycles—it may be beneficial to treat with FVD regimen
- Consider adding FARYDAK to maximise the clinical potential of BTZ/dex
Deciding if a patient is right for FARYDAK regimen
My response to BTZ was good.
After my first relapse, I was treated to progression with an IMiD. I was able to stay in remission for a while, but now I’ve relapsed.
What more can I do?
- 62-year-old male
- Has mild renal impairment
- Received autologous stem cell transplantation (ASCT)
- Achieved ≥PR with first-line treatment of BTZ/dex